纳米酶:与神经退行性疾病作斗争中的创新疗法
Carmen Duță1, Carmen Beatrice Dogaru1, Corina Muscurel1
1Department of Biochemistry, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
International journal of molecular sciences
|May 7, 2025
概括
纳米酶,具有类似酶活性的纳米材料,通过减少氧化应激和炎症来治疗神经退行性疾病有望出现. 这些工程纳米粒子提供了一种新的治疗策略,以保护神经元并改善患者的治疗结果.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 神经科学是一个神经科学.
背景情况:
- 像阿尔茨海默氏症和帕金森氏症这样的神经退行性疾病,由于神经元的逐渐损伤和缺乏治疗方法,造成了重大的全球健康挑战.
- 关键的病理特征包括氧化应激,蛋白质错折和神经炎症,导致神经元死亡.
- 目前的治疗方法有限,需要新的治疗方法.
研究的目的:
- 审查纳米酶在对抗神经退行性疾病中的氧化应激和炎症方面的多方面的作用.
- 探索纳米酶在神经退行性疾病中的设计,功能和治疗潜力.
- 突出纳米酶作为阻止疾病进展和改善患者结果的有希望的策略.
主要方法:
- 关于纳米酶及其在神经退行性疾病模型中的应用的最新科学文献的综述.
- 纳米酶性质的分析,包括抗氧化活性,ROS清理和表面修饰以实现目标传递.
- 关于纳米酶在应对氧化应激和蛋白质聚合方面的双重作用的综合发现.
主要成果:
- 纳米酶表现出强大的抗氧化特性,有效地清除反应性氧物种 (ROS) 并恢复氧化还原平衡.
- 工程纳米材料在生物医学应用中显示出有针对性交付和增强生物相容性的潜力.
- 纳米酶在缓解神经炎症和解决诸如蛋白质聚合等病理特征方面表现有前途.
结论:
- 纳米酶代表了神经退行性疾病的创新治疗策略.
- 它们抵消氧化应激和炎症的能力为神经保护提供了一个主动的方法.
- 对纳米酶设计和功能的进一步研究可能会导致阿尔茨海默氏症和帕金森病等疾病的改善治疗方法.
相关概念视频
siRNA - Small Interfering RNAs
16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Parkinson's Disease: Overview
319
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
319


